Alternative splicing is a widespread mechanism for post-transcriptional control of gene expression, and accounts for a large fraction of proteomic diversity. This process is also frequently misregulated in cancer, and appears to contribute to various changes associated with transformation. This project explores the molecular mechanisms through which the members of two conserved families of RNA-binding proteins regulate alternative splicing, and the range of pre-mRNA targets each of them controls in the context of transformation. Overexpression of these factors can promote tumorigenesis, and apparently bypass the requirement for oncogene cooperation by controlling the expression of specific isoforms of several key members of oncogene and tumor-suppressor networks. The prevalence of this mechanism for tumor development in different types of human cancer will be studied, and its specific features will be dissected and compared in different contexts by genetic manipulation of the splicing factors in cell culture and in models of B-cell lymphoma, hepatocellular carcinoma,and breast carcinoma. Distinctive features ofpre- mRNA targets recognized by the splicing machinery will also be studied, both to understand the mechanism and specificity of this process and to facilitate the classification of mutations in cancer- susceptibility genes that result in defective mRNA and protein. By exploring a new pathway for tumor development,this study may define markers that facilitate early detection of genetic lesions leading to cancer, and it may also potentially uncover novel targets for cancer therapy. Improved prediction of mutations that cause defective RNA splicing will inform treatment decisions for individuals with genetic predisposition to cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA013106-40
Application #
8208589
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2011-12-31
Budget Start
2011-01-01
Budget End
2011-12-31
Support Year
40
Fiscal Year
2011
Total Cost
$595,451
Indirect Cost
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Li, Meng Amy; Amaral, Paulo P; Cheung, Priscilla et al. (2017) A lncRNA fine tunes the dynamics of a cell state transition involving Lin28, let-7 and de novo DNA methylation. Elife 6:
Diermeier, Sarah D; Spector, David L (2017) Antisense Oligonucleotide-mediated Knockdown in Mammary Tumor Organoids. Bio Protoc 7:
Pelossof, Raphael; Fairchild, Lauren; Huang, Chun-Hao et al. (2017) Prediction of potent shRNAs with a sequential classification algorithm. Nat Biotechnol 35:350-353
Roe, Jae-Seok; Hwang, Chang-Il; Somerville, Tim D D et al. (2017) Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell 170:875-888.e20
Zhang, Bin; Mao, Yuntao S; Diermeier, Sarah D et al. (2017) Identification and Characterization of a Class of MALAT1-like Genomic Loci. Cell Rep 19:1723-1738
Mu, Ping; Zhang, Zeda; Benelli, Matteo et al. (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355:84-88
Anczuków, Olga; Krainer, Adrian R (2016) Splicing-factor alterations in cancers. RNA 22:1285-301
Baker, Leena; BeGora, Michael; Au Yeung, Faith et al. (2016) Scribble is required for pregnancy-induced alveologenesis in the adult mammary gland. J Cell Sci 129:2307-15
Tasdemir, Nilgun; Banito, Ana; Roe, Jae-Seok et al. (2016) BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. Cancer Discov 6:612-29
Hossain, Manzar; Stillman, Bruce (2016) Opposing roles for DNA replication initiator proteins ORC1 and CDC6 in control of Cyclin E gene transcription. Elife 5:

Showing the most recent 10 out of 592 publications